Hypersensitivity classification according to the Gell and Coombs modified by Sell, Pichler, and ICON.
\r\n\tThis book will provide information about current status of soybean production, processing, utilization and actual food safety management system as well as science based approaches defining the future of soybean for human consumption and animal feed.
",isbn:"978-1-83881-019-1",printIsbn:"978-1-83881-018-4",pdfIsbn:"978-1-83881-020-7",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,hash:"4bc6f95dc8630c9a8be84bb46286c445",bookSignature:"Dr. Aleksandra Sudarić",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/6972.jpg",keywords:"soybean, production, processing, development, utilization, trade, breeding, biotechnology,\r\nsoybean food usage, health benefits, food safety, management, risk, legislative",numberOfDownloads:133,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"December 4th 2019",dateEndSecondStepPublish:"December 25th 2019",dateEndThirdStepPublish:"February 23rd 2020",dateEndFourthStepPublish:"May 13th 2020",dateEndFifthStepPublish:"July 12th 2020",remainingDaysToSecondStep:"18 days",secondStepPassed:!1,currentStepOfPublishingProcess:2,editedByType:null,kuFlag:!1,editors:[{id:"21485",title:"Dr.",name:"Aleksandra",middleName:null,surname:"Sudarić",slug:"aleksandra-sudaric",fullName:"Aleksandra Sudarić",profilePictureURL:"https://mts.intechopen.com/storage/users/no_image.jpg",biography:"Dr Aleksandra Sudarić was born in Osijek, Croatia. \r\n\r\nShe received her MSc in Plant Genetics and Breeding from the University of Zagreb, and Ph.D. in Plant Breeding from the University of Osijek. \r\n\r\nIn addition, she completed the training for the application of DNA-based marker technology at the University of Guelph (Guelph, Canada).\r\nDr. Sudarić has been working at the Agricultural Institute Osijek (Osijek, Croatia) as the senior research scientist. \r\n\r\nShe is the Head of the Department for breeding and genetics of industrial plants. \r\n\r\nThe focus of her scientific work is the soybean breeding with emphasis on the development of soybean varieties for the needs of the producers, processors and customers. \r\n\r\nDr. Sudaric has authored more than 140 scientific, professional and popular articles, three chapters and three books about soybean and more than 20 registered soybean varieties.",institutionString:"Agricultural Institute",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Agricultural Institute Osijek",institutionURL:null,country:{name:"Croatia"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"5",title:"Agricultural and Biological Sciences",slug:"agricultural-and-biological-sciences"}],chapters:[{id:"68701",title:"Nondestructive Evaluation of Inoculation Effects of AMF and Bradyrhizobium japonicum on Soybean under Drought Stress From Reflectance Spectroscopy",slug:"nondestructive-evaluation-of-inoculation-effects-of-amf-and-bradyrhizobium-japonicum-on-soybean-unde",totalDownloads:50,totalCrossrefCites:0,authors:[null]},{id:"69807",title:"Improving Seed Quality of Soybean Suitable for Growing in Europe",slug:"improving-seed-quality-of-soybean-suitable-for-growing-in-europe",totalDownloads:38,totalCrossrefCites:0,authors:[null]},{id:"69396",title:"Soybean Amino Acids in Health, Genetics, and Evaluation",slug:"soybean-amino-acids-in-health-genetics-and-evaluation",totalDownloads:46,totalCrossrefCites:0,authors:[null]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"305835",firstName:"Ketrin",lastName:"Polesak",middleName:null,title:"Mrs.",imageUrl:"https://mts.intechopen.com/storage/users/305835/images/9351_n.png",email:"ketrin@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"1484",title:"Soybean",subtitle:"Molecular Aspects of Breeding",isOpenForSubmission:!1,hash:"3bd8fd078e7df24f2eed6dc7bc226475",slug:"soybean-molecular-aspects-of-breeding",bookSignature:"Aleksandra Sudaric",coverURL:"https://cdn.intechopen.com/books/images_new/1484.jpg",editedByType:"Edited by",editors:[{id:"21485",title:"Dr.",name:"Aleksandra",surname:"Sudarić",slug:"aleksandra-sudaric",fullName:"Aleksandra Sudarić"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6418",title:"Hyperspectral Imaging in Agriculture, Food and Environment",subtitle:null,isOpenForSubmission:!1,hash:"9005c36534a5dc065577a011aea13d4d",slug:"hyperspectral-imaging-in-agriculture-food-and-environment",bookSignature:"Alejandro Isabel Luna Maldonado, Humberto Rodríguez Fuentes and Juan Antonio Vidales Contreras",coverURL:"https://cdn.intechopen.com/books/images_new/6418.jpg",editedByType:"Edited by",editors:[{id:"105774",title:"Prof.",name:"Alejandro Isabel",surname:"Luna Maldonado",slug:"alejandro-isabel-luna-maldonado",fullName:"Alejandro Isabel Luna Maldonado"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3794",title:"Swarm Intelligence",subtitle:"Focus on Ant and Particle Swarm Optimization",isOpenForSubmission:!1,hash:"5332a71035a274ecbf1c308df633a8ed",slug:"swarm_intelligence_focus_on_ant_and_particle_swarm_optimization",bookSignature:"Felix T.S. Chan and Manoj Kumar Tiwari",coverURL:"https://cdn.intechopen.com/books/images_new/3794.jpg",editedByType:"Edited by",editors:[{id:"252210",title:"Dr.",name:"Felix",surname:"Chan",slug:"felix-chan",fullName:"Felix Chan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"15492",title:"Quadratic D Stabilizable Satisfactory Fault-tolerant Control with Constraints of Consistent Indices for Satellite Attitude Control Systems",doi:"10.5772/15114",slug:"quadratic-d-stabilizable-satisfactory-fault-tolerant-control-with-constraints-of-consistent-indices-",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/15492.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/15492",previewPdfUrl:"/chapter/pdf-preview/15492",totalDownloads:1433,totalViews:50,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,dateSubmitted:"June 3rd 2010",dateReviewed:"September 14th 2010",datePrePublished:null,datePublished:"April 26th 2011",readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/15492",risUrl:"/chapter/ris/15492",book:{slug:"discrete-time-systems"},signatures:"Han Xiaodong and Zhang Dengfeng",authors:[{id:"19748",title:"Dr.",name:"Xiaodong",middleName:null,surname:"Han",fullName:"Xiaodong Han",slug:"xiaodong-han",email:"willing.dong@yahoo.com.cn",position:null,institution:null},{id:"24332",title:"Prof.",name:"Dengfeng",middleName:null,surname:"Zhang",fullName:"Dengfeng Zhang",slug:"dengfeng-zhang",email:"myfeidfzhang@yahoo.com.cn",position:null,institution:null}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"68",title:"Discrete Time Systems",subtitle:null,fullTitle:"Discrete Time Systems",slug:"discrete-time-systems",publishedDate:"April 26th 2011",bookSignature:"Mario Alberto Jordán",coverURL:"https://cdn.intechopen.com/books/images_new/68.jpg",licenceType:"CC BY-NC-SA 3.0",editedByType:"Edited by",editors:[{id:"152460",title:"Dr.",name:"Mario",middleName:"Alberto",surname:"Jordán",slug:"mario-jordan",fullName:"Mario Jordán"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"15489",title:"Real-time Recursive State Estimation for Nonlinear Discrete Dynamic Systems with Gaussian or non-Gaussian Noise",slug:"real-time-recursive-state-estimation-for-nonlinear-discrete-dynamic-systems-with-gaussian-or-non-gau",totalDownloads:1705,totalCrossrefCites:0,signatures:"Kerim Demirbas",authors:[{id:"20091",title:"Dr.",name:"Kerim",middleName:null,surname:"Demirbas",fullName:"Kerim Demirbas",slug:"kerim-demirbas"}]},{id:"15486",title:"Observers Design for a Class of Lipschitz Discrete-Time Systems with Time-Delay",slug:"observers-design-for-a-class-of-lipschitz-discrete-time-systems-with-time-delay",totalDownloads:1826,totalCrossrefCites:0,signatures:"Ali Zemouche and Mohamed Boutayeb",authors:[{id:"22990",title:"Dr.",name:"Zemouche",middleName:null,surname:"Ali",fullName:"Zemouche Ali",slug:"zemouche-ali"},{id:"22991",title:"Prof.",name:"Boutayeb",middleName:null,surname:"Mohamed",fullName:"Boutayeb Mohamed",slug:"boutayeb-mohamed"}]},{id:"15503",title:"Distributed Fusion Prediction for Mixed Continuous-Discrete Linear Systems",slug:"distributed-fusion-prediction-for-mixed-continuous-discrete-linear-systems",totalDownloads:1317,totalCrossrefCites:1,signatures:"Ha-ryong Song, Moon-gu Jeon and Vladimir Shin",authors:[{id:"16370",title:"Mr.",name:"Ha Ryong",middleName:null,surname:"Song",fullName:"Ha Ryong Song",slug:"ha-ryong-song"},{id:"16373",title:"Prof.",name:"Vladimir",middleName:null,surname:"Shin",fullName:"Vladimir Shin",slug:"vladimir-shin"}]},{id:"15505",title:"New Smoothers for Discrete-time Linear Stochastic Systems with Unknown Disturbances",slug:"new-smoothers-for-discrete-time-linear-stochastic-systems-with-unknown-disturbances",totalDownloads:1492,totalCrossrefCites:2,signatures:"Akio Tanikawa",authors:[{id:"19810",title:"Prof.",name:"Akio",middleName:null,surname:"Tanikawa",fullName:"Akio Tanikawa",slug:"akio-tanikawa"}]},{id:"15490",title:"On the Error Covariance Distribution for Kalman Filters with Packet Dropouts",slug:"on-the-error-covariance-distribution-for-kalman-filters-with-packet-dropouts",totalDownloads:1462,totalCrossrefCites:0,signatures:"Eduardo Rohr Damián Marelli, and Minyue Fu",authors:[{id:"19449",title:"Dr.",name:"Minyue",middleName:null,surname:"Fu",fullName:"Minyue Fu",slug:"minyue-fu"},{id:"22818",title:"Mr.",name:"Eduardo",middleName:null,surname:"Rohr",fullName:"Eduardo Rohr",slug:"eduardo-rohr"},{id:"22819",title:"Dr.",name:"Damian",middleName:null,surname:"Marelli",fullName:"Damian Marelli",slug:"damian-marelli"}]},{id:"15504",title:"Kalman Filtering for Discrete Time Uncertain Systems",slug:"kalman-filtering-for-discrete-time-uncertain-systems",totalDownloads:1638,totalCrossrefCites:0,signatures:"Rodrigo Souto, João Ishihara and Geovany Borges",authors:[{id:"16966",title:"Dr.",name:"Geovany",middleName:null,surname:"Borges",fullName:"Geovany Borges",slug:"geovany-borges"},{id:"20742",title:"Dr.",name:"Rodrigo",middleName:null,surname:"Souto",fullName:"Rodrigo Souto",slug:"rodrigo-souto"},{id:"20743",title:"Prof.",name:"João",middleName:"Yoshiyuki",surname:"Ishihara",fullName:"João Ishihara",slug:"joao-ishihara"}]},{id:"15497",title:"Stochastic Optimal Tracking with Preview for Linear Discrete Time Markovian Jump Systems",slug:"stochastic-optimal-tracking-with-preview-for-linear-discrete-time-markovian-jump-systems",totalDownloads:1176,totalCrossrefCites:8,signatures:"Gou Nakura",authors:[{id:"18676",title:"Dr.",name:"Gou",middleName:null,surname:"Nakura",fullName:"Gou Nakura",slug:"gou-nakura"}]},{id:"15498",title:"The Design of a Discrete Time Model Following Control System for Nonlinear Descriptor System",slug:"the-design-of-a-discrete-time-model-following-control-system-for-nonlinear-descriptor-system",totalDownloads:1448,totalCrossrefCites:0,signatures:"Shigenori Okubo and Shujing Wu",authors:[{id:"18825",title:"Prof.",name:"Shigenori",middleName:null,surname:"Okubo",fullName:"Shigenori Okubo",slug:"shigenori-okubo"},{id:"52697",title:"Dr.",name:"Shujing",middleName:null,surname:"Wu",fullName:"Shujing Wu",slug:"shujing-wu"}]},{id:"15507",title:"Output Feedback Control of Discrete-time LTI Systems: Scaling LMI Approaches",slug:"output-feedback-control-of-discrete-time-lti-systems-scaling-lmi-approaches",totalDownloads:2530,totalCrossrefCites:0,signatures:"Jun Xu",authors:[{id:"2670",title:"Dr.",name:"Jun",middleName:null,surname:"Xu",fullName:"Jun Xu",slug:"jun-xu"}]},{id:"15508",title:"Discrete Time Mixed LQR/H∞ Control Problems",slug:"discrete-time-mixed-lqr-h-control-problems",totalDownloads:2026,totalCrossrefCites:1,signatures:"Xiaojie Xu",authors:[{id:"20349",title:"Dr.",name:"Xiaojie",middleName:null,surname:"Xu",fullName:"Xiaojie Xu",slug:"xiaojie-xu"}]},{id:"15510",title:"Robust Control Design of Uncertain Discrete-Time Systems with Delays",slug:"robust-control-design-of-uncertain-discrete-time-systems-with-delays",totalDownloads:1799,totalCrossrefCites:0,signatures:"Jun Yoneyama, Yuzu Uchida and Shusaku Nishikawa",authors:[{id:"6944",title:"Dr.",name:"Jun",middleName:null,surname:"Yoneyama",fullName:"Jun Yoneyama",slug:"jun-yoneyama"},{id:"15518",title:"Dr.",name:"Yuzu",middleName:null,surname:"Uchida",fullName:"Yuzu Uchida",slug:"yuzu-uchida"},{id:"19809",title:"Mr.",name:"Shusaku",middleName:null,surname:"Nishikawa",fullName:"Shusaku Nishikawa",slug:"shusaku-nishikawa"}]},{id:"15492",title:"Quadratic D Stabilizable Satisfactory Fault-tolerant Control with Constraints of Consistent Indices for Satellite Attitude Control Systems",slug:"quadratic-d-stabilizable-satisfactory-fault-tolerant-control-with-constraints-of-consistent-indices-",totalDownloads:1433,totalCrossrefCites:0,signatures:"Han Xiaodong and Zhang Dengfeng",authors:[{id:"19748",title:"Dr.",name:"Xiaodong",middleName:null,surname:"Han",fullName:"Xiaodong Han",slug:"xiaodong-han"},{id:"24332",title:"Prof.",name:"Dengfeng",middleName:null,surname:"Zhang",fullName:"Dengfeng Zhang",slug:"dengfeng-zhang"}]},{id:"15509",title:"Discrete-Time Adaptive Predictive Control with Asymptotic Output Tracking",slug:"discrete-time-adaptive-predictive-control-with-asymptotic-output-tracking",totalDownloads:1391,totalCrossrefCites:2,signatures:"Chenguang Yang and Hongbin Ma",authors:[{id:"16406",title:"Dr.",name:"Chenguang",middleName:null,surname:"Yang",fullName:"Chenguang Yang",slug:"chenguang-yang"},{id:"20259",title:"Dr.",name:"Hongbin",middleName:null,surname:"Ma",fullName:"Hongbin Ma",slug:"hongbin-ma"}]},{id:"15496",title:"Decentralized Adaptive Control of Discrete-Time Multi-Agent Systems",slug:"decentralized-adaptive-control-of-discrete-time-multi-agent-systems",totalDownloads:1214,totalCrossrefCites:3,signatures:"Hongbin Ma, Chenguang Yang and Mengyin Fu",authors:[{id:"16406",title:"Dr.",name:"Chenguang",middleName:null,surname:"Yang",fullName:"Chenguang Yang",slug:"chenguang-yang"},{id:"20259",title:"Dr.",name:"Hongbin",middleName:null,surname:"Ma",fullName:"Hongbin Ma",slug:"hongbin-ma"},{id:"20339",title:"Prof.",name:"Meng-Yin",middleName:null,surname:"Fu",fullName:"Meng-Yin Fu",slug:"meng-yin-fu"}]},{id:"15494",title:"A General Approach to Discrete-Time Adaptive Control Systems with Perturbed Measures for Complex Dynamics - Case Study: Unmanned Underwater Vehicles",slug:"a-general-approach-to-discrete-time-adaptive-control-systems-with-perturbed-measures-for-complex-dyn",totalDownloads:1724,totalCrossrefCites:0,signatures:"Mario Alberto Jordán and Jorge Luis Bustamante",authors:[{id:"152460",title:"Dr.",name:"Mario",middleName:"Alberto",surname:"Jordán",fullName:"Mario Jordán",slug:"mario-jordan"},{id:"21178",title:"Dr.",name:"Jorge Luis",middleName:null,surname:"Bustamante",fullName:"Jorge Luis Bustamante",slug:"jorge-luis-bustamante"}]},{id:"15506",title:"Stability Criterion and Stabilization of Linear Discrete-time System with Multiple Time Varying Delay",slug:"stability-criterion-and-stabilization-of-linear-discrete-time-system-with-multiple-time-varying-dela",totalDownloads:1588,totalCrossrefCites:0,signatures:"Xie Wei",authors:[{id:"16322",title:"Dr.",name:"Wei",middleName:null,surname:"Xie",fullName:"Wei Xie",slug:"wei-xie"}]},{id:"15495",title:"Uncertain Discrete-Time Systems with Delayed State: Robust Stabilization with Performance Specification via LMI Formulations",slug:"uncertain-discrete-time-systems-with-delayed-state-robust-stabilization-with-performance-specificati",totalDownloads:1763,totalCrossrefCites:0,signatures:"Valter J. S. Leite, Michelle F. F. Castro, André F. Caldeira, Márcio F. Miranda and Eduardo N. Gonçalves",authors:[{id:"19903",title:"Prof.",name:"Valter J. S.",middleName:null,surname:"Leite",fullName:"Valter J. S. Leite",slug:"valter-j.-s.-leite"},{id:"19904",title:"Prof.",name:"Márcio F.",middleName:null,surname:"Miranda",fullName:"Márcio F. Miranda",slug:"marcio-f.-miranda"},{id:"19905",title:"Ms.",name:"Michelle F. F.",middleName:null,surname:"Castro",fullName:"Michelle F. F. Castro",slug:"michelle-f.-f.-castro"},{id:"19906",title:"Prof.",name:"Eduardo N.",middleName:null,surname:"Gonçalves",fullName:"Eduardo N. Gonçalves",slug:"eduardo-n.-goncalves"},{id:"24287",title:"BSc",name:"André F.",middleName:null,surname:"Caldeira",fullName:"André F. Caldeira",slug:"andre-f.-caldeira"}]},{id:"15493",title:"Stability Analysis of Grey Discrete Time Time-Delay Systems: A Sufficient Condition",slug:"stability-analysis-of-grey-discrete-time-time-delay-systems-a-sufficient-condition",totalDownloads:1438,totalCrossrefCites:1,signatures:"Wen-Jye Shyr and Chao-Hsing Hsu",authors:[{id:"17389",title:"Dr.",name:"Chao-Hsing",middleName:null,surname:"Hsu",fullName:"Chao-Hsing Hsu",slug:"chao-hsing-hsu"}]},{id:"15511",title:"Stability and L2 Gain Analysis of Switched Linear Discrete-Time Descriptor Systems",slug:"stability-and-l2-gain-analysis-of-switched-linear-discrete-time-descriptor-systems",totalDownloads:1761,totalCrossrefCites:0,signatures:"Guisheng Zhai",authors:[{id:"16223",title:"Dr.",name:"Guisheng",middleName:null,surname:"Zhai",fullName:"Guisheng Zhai",slug:"guisheng-zhai"}]},{id:"15487",title:"Robust Stabilization for a Class of Uncertain Discrete-time Switched Linear Systems",slug:"robust-stabilization-for-a-class-of-uncertain-discrete-time-switched-linear-systems",totalDownloads:1396,totalCrossrefCites:0,signatures:"Songlin Chen, Yu Yao and Xiaoguan Di",authors:[{id:"17490",title:"Dr.",name:"Songlin",middleName:null,surname:"Chen",fullName:"Songlin Chen",slug:"songlin-chen"}]},{id:"15501",title:"Half-overlap Subchannel Filtered MultiTone Modulation and Its Implementation",slug:"half-overlap-subchannel-filtered-multitone-modulation-and-its-implementation",totalDownloads:2673,totalCrossrefCites:0,signatures:"Pavel Silhavy and Ondrej Krajsa",authors:[{id:"16581",title:"Dr.",name:"Pavel",middleName:null,surname:"Silhavy",fullName:"Pavel Silhavy",slug:"pavel-silhavy"},{id:"20819",title:"Ing",name:"Ondrej",middleName:null,surname:"Krajsa",fullName:"Ondrej Krajsa",slug:"ondrej-krajsa"}]},{id:"15502",title:"Adaptive Step-size Order Statistic LMS-based Time-domain Equalisation in Discrete Multitone Systems",slug:"adaptive-step-size-order-statistic-lms-based-time-domain-equalisation-in-discrete-multitone-systems",totalDownloads:1705,totalCrossrefCites:0,signatures:"Suchada Sitjongsataporn and Peerapol Yuvapoositanon",authors:[{id:"16087",title:"Dr.",name:"Suchada",middleName:null,surname:"Sitjongsataporn",fullName:"Suchada Sitjongsataporn",slug:"suchada-sitjongsataporn"},{id:"16095",title:"Dr.",name:"Peerapol",middleName:null,surname:"Yuvapoositanon",fullName:"Peerapol Yuvapoositanon",slug:"peerapol-yuvapoositanon"}]},{id:"15491",title:"Discrete-Time Dynamic Image-Segmentation System",slug:"discrete-time-dynamic-image-segmentation-system",totalDownloads:1666,totalCrossrefCites:0,signatures:"Ken’ichi Fujimoto, Mio Kobayashi and Tetsuya Yoshinaga",authors:[{id:"17374",title:"Dr.",name:"Ken'ichi",middleName:null,surname:"Fujimoto",fullName:"Ken'ichi Fujimoto",slug:"ken'ichi-fujimoto"},{id:"17376",title:"Dr.",name:"Tetsuya",middleName:null,surname:"Yoshinaga",fullName:"Tetsuya Yoshinaga",slug:"tetsuya-yoshinaga"},{id:"17377",title:"Ms.",name:"Mio",middleName:null,surname:"Musashi",fullName:"Mio Musashi",slug:"mio-musashi"}]},{id:"15512",title:"Fuzzy Logic Based Interactive Multiple Model Fault Diagnosis for PEM Fuel Cell Systems",slug:"fuzzy-logic-based-interactive-multiple-model-fault-diagnosis-for-pem-fuel-cell-systems",totalDownloads:1687,totalCrossrefCites:1,signatures:"Yan Zhou, Dongli Wang, Jianxun Li, Lingzhi Yi and Huixian Huang",authors:[{id:"16494",title:"Dr.",name:"Yan",middleName:null,surname:"Zhou",fullName:"Yan Zhou",slug:"yan-zhou"},{id:"19851",title:"Dr.",name:"Dongli",middleName:null,surname:"Wang",fullName:"Dongli Wang",slug:"dongli-wang"},{id:"24015",title:"Prof.",name:"Jianxun",middleName:null,surname:"Li",fullName:"Jianxun Li",slug:"jianxun-li"},{id:"24016",title:"Prof.",name:"Huixian",middleName:null,surname:"Huang",fullName:"Huixian Huang",slug:"huixian-huang"}]},{id:"15488",title:"Discrete Time Systems with Event-Based Dynamics: Recent Developments in Analysis and Synthesis Methods",slug:"discrete-time-systems-with-event-based-dynamics-recent-developments-in-analysis-and-synthesis-method",totalDownloads:1160,totalCrossrefCites:2,signatures:"Edgar Delgado-Eckert, Johann Reger and Klaus Schmidt",authors:[{id:"19545",title:"Dr.",name:"Edgar",middleName:null,surname:"Delgado-Eckert",fullName:"Edgar Delgado-Eckert",slug:"edgar-delgado-eckert"},{id:"20929",title:"Dr.",name:"Johann",middleName:null,surname:"Reger",fullName:"Johann Reger",slug:"johann-reger"},{id:"20930",title:"Dr.",name:"Klaus",middleName:null,surname:"Schmidt",fullName:"Klaus Schmidt",slug:"klaus-schmidt"}]},{id:"15499",title:"Discrete Deterministic and Stochastic Dynamical Systems with Delay - Applications",slug:"discrete-deterministic-and-stochastic-dynamical-systems-with-delay-applications",totalDownloads:2094,totalCrossrefCites:0,signatures:"Mihaela Neamţu and Dumitru Opris",authors:[{id:"16253",title:"Dr.",name:"Dumitru",middleName:null,surname:"Opris",fullName:"Dumitru Opris",slug:"dumitru-opris"},{id:"16255",title:"Prof.",name:"Mihaela",middleName:null,surname:"Neamtu",fullName:"Mihaela Neamtu",slug:"mihaela-neamtu"}]},{id:"15500",title:"Multidimensional Dynamics: From Simple to Complicated",slug:"multidimensional-dynamics-from-simple-to-complicated",totalDownloads:1745,totalCrossrefCites:0,signatures:"\ufeffKang-Ling Liao, Chih-Wen Shih and Jui-Pin Tseng",authors:[{id:"20010",title:"Prof.",name:"Chih-Wen",middleName:null,surname:"Shih",fullName:"Chih-Wen Shih",slug:"chih-wen-shih"},{id:"20344",title:"Dr.",name:"Kang-Ling",middleName:null,surname:"Liao",fullName:"Kang-Ling Liao",slug:"kang-ling-liao"},{id:"20345",title:"Dr.",name:"Jui-Pin",middleName:null,surname:"Tseng",fullName:"Jui-Pin Tseng",slug:"jui-pin-tseng"}]}]},relatedBooks:[{type:"book",id:"4457",title:"Finite Element Analysis",subtitle:null,isOpenForSubmission:!1,hash:"285298bf100533ffcdc1a1a969b29177",slug:"finite-element-analysis",bookSignature:"David Moratal",coverURL:"https://cdn.intechopen.com/books/images_new/4457.jpg",editedByType:"Edited by",editors:[{id:"9850",title:"Dr.",name:"David",surname:"Moratal",slug:"david-moratal",fullName:"David Moratal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"11974",title:"Finite Element Analysis on Strains of Viscoelastic Human Skull and Duramater",slug:"finite-element-analysis-on-strains-of-viscoelastic-human-skull-and-duramater",signatures:"Xianfang Yue",authors:[null]},{id:"11975",title:"Application of Finite Element Analysis in Dentistry",slug:"application-of-finite-element-analysis-in-dentistry",signatures:"Ming-Lun Hsu and Chih-Ling Chang",authors:[null]},{id:"11977",title:"Finite Element Analysis for Dental Prosthetic Design",slug:"finite-element-analysis-for-dental-prosthetic-design",signatures:"Akikazu Shinya and Daiichiro Yokoyama",authors:[null]},{id:"11985",title:"Application of Finite Element Analysis in Root Canal Therapy",slug:"application-of-finite-element-analysis-in-root-canal-therapy",signatures:"Tao Hu, Ran Cheng, Meiying Shao, Hui Yang, Ru Zhang, Qianhua Gao and Liyang Guo",authors:[null]},{id:"11986",title:"Finite element simulation. Applications in Orthopaedics and Traumatology",slug:"finite-element-simulation-applications-in-orthopaedics-and-traumatology-",signatures:"Antonio Herrera",authors:[null]},{id:"11987",title:"Finite Element Analysis in Orthopaedic Biomechanics",slug:"finite-element-analysis-in-orthopaedic-biomechanics",signatures:"Daniel Kluess",authors:[null]},{id:"11992",title:"Orthopaedic Biomechanics: A Practical Approach to Combining Mechanical Testing and Finite Element Analysis",slug:"orthopaedic-biomechanics-a-practical-approach-to-combining-mechanical-testing-and-finite-element-ana",signatures:"Rad Zdero and Habiba Bougherara",authors:[null]},{id:"11993",title:"Finite Element Modeling for a Morphometric and Mechanical Characterization of Trabecular Bone from High Resolution Magnetic Resonance Imaging",slug:"finite-element-modeling-for-a-morphometric-and-mechanical-characterization-of-trabecular-bone-from-h",signatures:"Angel Alberich-Bayarri, Luis Marti-Bonmati, M. Angeles Perez, Juan José Lerma and David Moratal",authors:[null]},{id:"11994",title:"Finite Element Modelling of Human Lumbar Spine",slug:"finite-element-modelling-of-human-lumbar-spine-",signatures:"Marta Kurutz",authors:[null]},{id:"11995",title:"Analysis of Human Pressure Ulcer and Cushion Pads for Its Prevention",slug:"analysis-of-human-pressure-ulcer-and-cushion-pads-for-its-prevention",signatures:"Masataka Akimoto",authors:[null]},{id:"12000",title:"Microfinite Element Modeling for Evaluating Polymer Scaffolds Architecture and their Mechanical Properties from microComputed Tomography",slug:"microfinite-element-modeling-for-evaluating-polymer-scaffolds-architecture-and-their-mechanical-prop",signatures:"Angel Alberich-Bayarri, Manuel Salmeron-Sanchez, M. Angeles Perez and David Moratal",authors:[null]},{id:"12001",title:"Computational Modelling of Auxetics",slug:"computational-modelling-of-auxetics",signatures:"Tomasz Strek, Bogdan Maruszewski, Artur A. Pozniak and Krzysztof W. Wojciechowski",authors:[null]},{id:"12002",title:"Modelling of Thermoplastic Fibre-Composites and Finite Element Simulation of Mechanical Properties",slug:"modelling-of-thermoplastic-fibre-composites-and-finite-element-simulation-of-mechanical-properties",signatures:"Robert Shanks",authors:[null]},{id:"12003",title:"Dynamic Finite Element Analysis of Nonlinear Isotropic Hyperelastic and Viscoelastic Materials for Thermoforming Applications",slug:"dynamic-finite-element-analysis-of-nonlinear-isotropic-hyperelastic-and-viscoelastic-materials-for-t",signatures:"Fouad Erchiqui",authors:[null]},{id:"12096",title:"Finite Element Analysis and Fracture in Viscoelastic Materials by Mv Integral",slug:"finite-element-analysis-and-fracture-in-viscoelastic-materials-by-m-v-integral",signatures:"Rostand Moutou Pitti, Frederic Dubois and Mustapha Taazount",authors:[null]},{id:"12097",title:"Finite Element Modelling of Elastic-Plastic Contact of Rough Surfaces",slug:"finite-element-modelling-of-elastic-plastic-contact-of-rough-surfaces",signatures:"Jamil Abdo, Danish Haneef and Abdullah Al-Shabibi",authors:[null]},{id:"12098",title:"Numerical Study of Backward Extrusion Process Using Finite Element Method",slug:"numerical-study-of-backward-extrusion-process-using-finite-element-method",signatures:"Karen Abrinia, and Sakineh Orangi",authors:[null]},{id:"12099",title:"Finite Element Analysis on V-Die Bending Process",slug:"finite-element-analysis-on-v-die-bending-process",signatures:"Sutasn Thipprakmas",authors:[null]},{id:"12100",title:"Analysis of Welding Residual Stresses and Its Applications",slug:"analysis-of-welding-residual-stresses-and-its-applications",signatures:"Byeong-Choon Goo, Jung-Won Seo and Seung-Yong Yang",authors:[null]},{id:"12101",title:"Dynamic Finite Element Analysis on Underlay Microstructure of Cu/low-k Wafer during Wirebonding",slug:"dynamic-finite-element-analysis-on-underlay-microstructure-of-cu-low-k-wafer-during-wirebonding",signatures:"Hsiang-Chen Hsu, Chin-Yuan Hu, Wei-Yao Chang, Chang-Lin Yeh and Yi-Shao Lai",authors:[null]},{id:"12102",title:"Finite Element Analysis of Deformation and Fracture of Cylindrical Tubes under Internal Moving Pressures",slug:"finite-element-analysis-of-deformation-and-fracture-of-cylindrical-tubes-under-internal-moving-press",signatures:"Majid Mirzaei",authors:[null]},{id:"12112",title:"FE Analysis of Evolution of Defects during Rolling",slug:"fe-analysis-of-evolution-of-defects-during-rolling",signatures:"Hailiang YU",authors:[null]},{id:"12113",title:"Finite Element Analysis of Strip and Rolling Mills",slug:"-finite-element-analysis-of-strip-and-rolling-mills",signatures:"Jian-guo Cao, Jie Zhang, Ning Kong and Kai-fu Mi",authors:[null]},{id:"12114",title:"Strain Variations on Rolling Condition in Accumulative Roll-Bonding by Finite Element Analysis",slug:"strain-variations-on-rolling-condition-in-accumulative-roll-bonding-by-finite-element-analysis",signatures:"Tadanobu Inoue",authors:[null]},{id:"12115",title:"Finite Element Analysis of Wall Deflection And Ground Movements Caused by Braced Excavations",slug:"finite-element-analysis-of-wall-deflection-and-ground-movements-caused-by-braced-excavations",signatures:"Gordon Tung-Chin Kung",authors:[null]},{id:"12116",title:"Vehicle-Bridge Dynamic Interaction Using Finite Element Modelling",slug:"vehicle-bridge-dynamic-interaction-using-finite-element-modelling",signatures:"Arturo Gonzalez",authors:[null]},{id:"12117",title:"Finite Element Modelling of Sound Transmission Loss in Reflective Pipe",slug:"finite-element-modelling-of-sound-transmission-loss-in-reflective-pipe",signatures:"Tomasz Strek",authors:[null]}]}]},onlineFirst:{chapter:{type:"chapter",id:"69136",title:"Eosinophilic Disorders: Extrinsic and Intrinsic Immune Response, New Diagnostic Perspectives, and Therapeutic Alternatives",doi:"10.5772/intechopen.89229",slug:"eosinophilic-disorders-extrinsic-and-intrinsic-immune-response-new-diagnostic-perspectives-and-thera",body:'\nEosinophils are leukocytes (white cells) found in the peripheral blood, hematopoietic, lymphatic organs, the bone marrow, spleen, and thymus, and can migrate to connective tissues and digestive tract; they are part of the group of leukocytes called granulocytes, along with basophils and neutrophils. They were described by P. Ehrlich in 1879 calling them eosinophils because their acidic granules in the cytoplasm were stained by their affinity dye aniline-eosin giving them the form of red-orange ammunition observed by optical microscopy: They are rounded cells from 8 to 15 μm in diameter, with a bilobed core with a fine nuclear bridge joining both lobes [1].
\nIdentification and quantification.
\nMethodology: Manual count in Neubauer chamber and automatic hematology analyzer using impedance and colorimetry and flow cytometry CD16 (FcƳRIII-CD16). Under normal conditions peripheral blood eosinophils represent 1–5% of total leukocytes, with an upper limit of 0.4 × 109 L,, the absolute eosinophilic count (AEC) of 350–500/mm3 and in children is greater than 0.75 × 109 L, increasing the number of eosinophils (eosinophilia) to more than 3–5 times which is indicative of an activity of infectious, parasitic, allergic, and eosinophilic and hypereosinophilic disorders [1, 4, 5, 7, 8].
\nThey originate in the bone marrow, by a process of maturation and differentiation that lasts approximately 8 days (hematopoiesis) from a pluripotential precursor cell (stem cell) differentiating itself as myeloid granulocytic line, under the influence of IL-3, IL-4 - granulocytic colony stimulation factor (GM-CSF) of eotaxin; evolving toward a mixed eosinophil-basophilic precursor and then differentiating toward eosinophils by action of IL-3, GM-CSF, and especially IL-5, they have a survival of 6–12 hours before moving to tissues where they remain between 2 and 5 days; once there is a stimulus, they respond by exercising their multiple functions regulated by T lymphocytes (Figure 1) [1, 2, 4].
\nScheme representing hematopoiesis, origin of eosinophil and its main functions associated with eosinophilic disorders. Molecules expressed on its surface (FcεRI-CD23-IgE). CCR4, CD88,H4R. Adhesion molecules: CD11b, CD11c, CD62L, and chemokines that attract eosinophils from blood to tissues [3, 5].
The text begins with: Its main functions are the defense against parasites, helminths, nematodes, participate in allergic responses, inflammatory processes, restoration, and tissue repair; since they have specific chemotactic receptors on their membrane, eotaxin, cytokines (IL-3 -IL-5 and GM-CSF), eosinophil chemotactic factor of anaphylaxis (ECF-A); and nonspecific such as f MLP (from the wall of bacteria), complement activation products (C3a, C5a, C6, and C7), platelet-activating factor (PAF), leukotrienes (LTB 4 and LTD 4), histamine and IL-8. Diapedesis is mainly performed by integrins to adhere to the vascular endothelium (e.g., LFA-1-ICAM-1, the VLA-VCAM-1) and other multiple antibody receptors: IgA (Fc α R1-CD89), (FcεRIII-CD23-IgE), (FcƳεRI-degranulation), (FcƳRI-CD64-IgG1, IgG3 respiratory burst induction of microbial death), (FcƳA-CD32-Ig G1-degranulation), (FcƳRIIB-CD32-IgG1-No Phagocytosis, inhibition of cellular activity) (Figure 1) [2, 4, 6].
\nGranular content: Eosinophil mature contains in its cytoplasm primary granules rich in phospholipase A, rich in crystalline proteins of Charcot-Leyden-specific secondary granules containing the major or main basic protein (MBP), the eosinophilic peroxidase (EPO), eosinophilic protein (ECP)), and eosinophil-derived neurotoxin (EDN) that also appears in basophils and neutrophils; its response capacity is less than 1 hour, small granules containing arylsulfatase B and acid phosphatase and five lipid bodies main source of arachidonic acid, can be presenting cells, proliferation of T lymphocytes and basophils are capable of deliberating more than 35 cytokines, chemokines, and growth factors (Figure 1) [8, 9].
\nThe severity of eosinophilia has been arbitrarily divided into mild (AEC from the upper limit of normal to 1500/mm3), moderate (AEC 1500–5000/mm3), and severe (AEC >5000/mm3).
\nThe classification of eosinophilic diseases was revised in 2008 and reaffirmed in 2016. In 2017 its diagnosis, risk stratification (prognosis), and management (treatment) proposed by the World Health Organization were covered [10].
\nEosinophilic diseases can be classified in two types: primary, intrinsic hematology due to clonal disorders, and secondary, extrinsic or reactive disorders to an external cause that cause damage to different organs. Primary eosinophilias or clonal disorders can be diagnosed by studying the blood and bone marrow by the following methods: standard cytogenetics, molecular biology with monoclonal antibodies, flow cytometry, in situ hybridization, and evaluation of T cell clonality.
\nThe major category of primary diseases corresponds to myeloid/lymphoid neoplasms with eosinophilia and rearrangements PDGFRA, PDGFRB, or FGR1; with PCMiJAK2 and MPN, a subtype of chronic eosinophilic leukemia or not specified by CEL-NOS, there is another lymphoid-eosinophilic variant of aberrant T cell clone.
\nThe modern definition of hypereosinophilic syndrome (HES) is a vestige of the historical criteria outlined by Chusid and colleagues in 1975: The absolute eosinophil count is >1500/mm3 for more than 6 months, and tissue damage is present [10, 11].
\nThe Working Conference on Eosinophil Disorders and Syndromes proposed a new terminology for eosinophilic syndromes. Hypereosinophilia (HE) for persistent and marked eosinophilia (AEC >1500/mm3) in turn, HE subtypes were divided into a hereditary (familiar) variant (HEfa); HE of undetermined significance (HEus), primary (clonal-neoplastic), HE produced by clonal/neoplastic eosinophils (HEn), and secondary (reactive) (HEr) can be considered a provisional diagnosis until a primary or secondary cause of eosinophilia is ascertained [12].
\nTo have to a better understanding of the pathogenetic aspects of eosinophilia, other classifications of eosinophilic diseases were generated according to the site of eosinophilic infiltration associated with organ damage and dysfunction. The primary cause of eosinophilia located within the eosinophils (and/or eosinophil precursors) themselves or in other cells, similar to allergic diseases, can be divided in IgE-mediated (extrinsic) and non-IgE-mediated (intrinsic) diseases; the terms extrinsic and intrinsic eosinophilic disorders indicate whether the primary cause of eosinophilia is inside or outside the eosinophil lineage [11].
\nChronic eosinophilic leukemias belong to a special group of chronic myeloid leukemias, in which eosinophil differentiation is dominant, resulting in blood eosinophil counts of greater than 1500/mm3. However, other lineages are also affected, because the disease is the result of a mutation in a pluripotent hematopoietic stem cell. The chromosomal translocations related to breakpoints on chromosome 8p11 result in fibroblast growth factor receptor 1 fusion genes with increased kinase activity causing the so-called 8p11 syndrome. The increase in tyrosine kinase activity is caused by gene 1 and the growth factor, and this leukemia has a worse prognosis, which transforms chronic leukemia to an acute, 1–2 years. Another type of cause may be the increase in tyrosine kinase by fusion of the platelet growth factor alpha receptor genes (PDGFRA). PDGFRA is fused by the Fip1-like 1 (FIP1L1) gene as a result of a 4q12.9 chromosome damage. This is both in eosinophils and in other hematopoietic lineages such as neutrophils, monocytes, lymphocytes, and mast cells. This type of leukemia is pluripotent hematopoietic stem cell which responds to the tyrosine kinase inhibitor (imatinib) [10, 11].
\nMutations in multipotent myeloid stem cells: In the chronic myeloid leukemias with eosinophilia, eosinophils are part of the clone. This is because eosinophil differentiation is often not as prominent as other myeloid cells, such as monocytes, which also show increased differentiation. Chromosomal translocations related to breakpoints on chromosome 5q33 are common and represent the basis for the formation of platelet-derived growth factor receptor b (PDGFRB) fusion genes; this result increases the tyrosine kinase activity. There are patients with positive Philadelphia chromosome who can develop chronic leukemia with eosinophilia due to two factors: fusion by breakpoint cluster region-Abelson (ABL) and fusion of transcription gene 6 (ETV6). Marked eosinophilia often associated with a cytogenetic evolution and other accelerated phases of ABL can occur during an acute transformation; ABL may be fused with the transcription factor E26 by means of variant ETV6 triggering chronic leukemia [10].
\nMyelodysplastic syndromes: During hematopoiesis there may be an inefficient process in the differentiation of stem cell by mutations, malignant clones producing myelodysplastic syndromes that lead to myeloproliferative diseases such as polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. The exact molecular genetic abnormalities resulting in eosinophilia in these disorders remain to be determined [10, 11].
\nT cell-mediated eosinophilias: The common diseases are allergic rhinoconjunctivitis, bronchial asthma, drug allergic, eosinophilic esophagitis, and atopic dermatitis. Eosinophilia and IgE production due to the polarization of TH2 cells whose causes are extrinsic or external by stimulation of environmental immunogens or chemical compounds, which are presented by APC-MHC, stimulating the release of pro-inflammatory cytokines (IL4, IL5, and IL13), induce the increase in eosinophils of IgE survival, high affinity receptors with PKC activation, cross-linking and signaling for histamine release, as well as vasoactive amines that produce inflammatory processes and organ damage [10, 11].
\nInfectious diseases: TH2 inflammatory responses are induced by helminths; these responses are characterized by IgE antibody production and eosinophilia; both have been implicated in mediating protective immunity to the parasites. In contrast, there is little doubt that eosinophils contribute to tissue damage and therefore to the pathogenesis of these infections.
\nViral infections are not common; however, when virus-specific T cells are generated in a TH2 environment, they can also release IL-5 and therefore trigger eosinophilia. In chronic rhinosinusitis, eosinophilia is related to fungal infections with certain molds (e.g., Alternaria) which is present in the nasal and paranasal cavities [8, 10, 11].
\nAutoimmune diseases: Because these diseases are often associated with a TH1-associated inflammatory response, eosinophilia is not frequent, but in systemic sclerosis, levels of major basic protein and extracellular major basic protein depositions were observed in skin and lung tissues. In primary biliary cirrhosis, eosinophilia is a distinctive feature that might be useful in the diagnosis of the disease [10, 11, 14].
\nGraft-versus-host diseases: When an allogeneic bone marrow transplant is carried out and there are differences in MHC molecule polymorphism, these can be recognized by the immune system, and responses can be made against the alloantigens, producing graft-versus- host-disease (GVHDs), carrying out a reaction antigen antibody, cellular or cytotoxic that produces lysis and destruction in specific organs (skin, liver, and gastrointestinal tract mainly).
\nDrug-induced diseases: Hypersensitivity drug reactions may present in some cases increased eosinophils. The manifestations range from maculopapular rashes of the skin to severe life-threatening drug reactions with eosinophilia and systemic symptoms (DRESS). Drugs and their metabolites can produce hypersensitivity by means of mechanisms mediated by APC-MHC TCR pi concept, generating TH2 polarity or TH1 with memory T cells [10, 11, 14].
\nThere are other subgroups of this syndrome as episodic angioedema and hereditary eosinophilia. Where there is evidence of mechanism mediated by IL-5-producing T cells [8].
\nSevere primary (IL-5) and secondary immunodeficiencies (HIV) are associated with eosinophilia when there is polarization of TH2 by the immunogen (allergen) or drug (antiretroviral); infections such as tuberculosis are the cause of infections and resistance to treatment (Figure 2) [11].
\nDiagnostic algorithm for patients with hypereosinophilia. Due to the fact that eosinophilia can occur in different pathologies, an exclusion of the unlikely causes for hypereosinophilia is performed, in addition to a three-step follow-up treatment with imatinib due to mutation processes that is considered. Laboratory tests would be at the discretion of the doctor according to the medical history and the search according to the type of response to the genes involved [12].
Corticosteroids should be considered a first-line treatment, which are potent anti-eosinophil agents, effective in producing rapid reductions. Maximal dose was 1 mg × kg 2 months, with symptom control and reduction of the eosinophil count to below 1500/mm3 after 1 month of treatment.
\nHydroxyurea is an effective first-line agent for HES which may be used in conjunction with corticosteroids or in steroid nonresponders. A typical starting dose is 500–1000 mg daily which can serve as effective palliative to control leukocytosis and eosinophilia but with no proven role in favorably altering the natural history of HES or CEL-NOS (Figure 2) [10, 12, 13].
\nIFN-a has demonstrated hematologic responses and reversion of organ injury in patients with HES and CEL-NOS refractory to therapies including prednisone and/or hydroxyurea. Remissions have been associated with improvement in clinical symptoms and organ disease, including hepatosplenomegaly, cardiac and thromboembolic complications, mucosal ulcers, and skin involvement [8, 10, 11, 12].
\nMepolizumab anti-IL-5 antibody is a fully monoclonal IgG antibody that inhibits binding of IL-5 chain of the IL-5 receptor expressed on eosinophils [8, 13].
\nAlemtuzumab is an anti-CD52 monoclonal antibody that has been evaluated in idiopathic HES based on expression of the CD52 antigen on eosinophils. In patients with refractory HES, alemtuzumab was administered intravenously at a dose of 5–30 mg once to thrice weekly.
\nBone marrow/peripheral blood stem cell allogeneic transplantation has been attempted in patients with aggressive disease; a disease-free survival ranging from 8 months to 5 years has been reported.
\nImatinib is a small-molecule tyrosine kinase inhibitor 100 mg per day; it also shows activity against platelet-derived growth factor receptor (PDGF-R), c-Kit, Abl-related gene (ARG), and their fusion proteins while sparing other kinases (Figure 3) [10].
\nDiagnostic and treatment algorithm based on revised 2016 WHO classification of eosinophilic disorders. According to the algorithm, the type of eosinophilia can be monitored according to the cases where other drugs other than imatinib should be used, with three pathological options being present: chronic leukemia with eosinophilia, idiopathic hypereosinophilia, and lymphocyte variant, all share the administration of imatinib and corticosteroids (idiopathic hypereosinophilia and lymphocyte variant) [10].
Mastocytosis: Develops from a neoplastic proliferation of mast cells. It develops from a neoplastic clonal proliferation of mastocytes that accumulate in one or more organ systems and are organize as compact cohesive aggregate groups or multifocal groups of abnormal mastocytes. This disorder is diverse; it can be found as cutaneous lesions that may naturally recede, to highly aggressive neoplasias related with multiple organ failure and short outliving. Mastocytosis subtypes are principally characterized by the clinical manifestations and the spread of the disease. When cutaneous mastocytosis (CM) occurs, mastocyte infiltration is restricted to the skin, whereas systemic mastocytosis (SM) includes at least one extracutaneous organ, with or without skin lesions. Mastocytosis must be distinguished from mastocyte hyperplasia or from the mastocyte activation states, without the morphological or molecular abnormalities that characterize neoplastic proliferation [15]. The WHO classification includes seven types:
Cutaneous mastocytosis
Indolent systemic mastocytosis (ISM)
Systemic mastocytosis with associated clonal, hematologic non-mast cell lineage disease (SM-AHNMD)
Aggressive systemic mastocytosis (ASM)
Mast cell leukemia (MCL)
Mast cell sarcoma (MCS)
Extracutaneous mastocytoma
Hypereosinophilic syndrome (HES): It has been described as a condition associated with persistent eosinophilia in the peripheral blood, organ damage, and exclusion of any other underlying disease or condition that may explain eosinophilia or organ damage [7, 16, 17, 18, 19]. The diagnostic algorithm must begin with the evaluation of peripheral blood hypereosinophilia (HE), defined as a persistent increase of blood eosinophils, above 1.5 X 109/L blood [7, 16, 17, 18]. The term “tissue HE” has also been proposed, and it may be useful in the evaluation and the classification of the disorders related to HES [16, 19]. The establishment of an HES diagnosis must be considered: (a) the existence of an underlying disease or condition and (b) the presence of clinical signs and symptoms or laboratory abnormalities that show organ damage induced by HE (HES) [19]. There are four important groups of underlying disorders in patients with documented HES:
Hematopoietic neoplasias
Other neoplasias (non-hematopoietic) (paraneoplastic HE)
Common allergic, reactive, or immunological conditions
Infrequent clinical syndromes that present HE, including rare hereditary disorders [19]
Lymphoid and myeloid leukemias: Many hematologic disorders may present eosinophilia, but only a few present clonal (primary) neoplasias, and just a small number of neoplasms present HE and organ damage. Myeloid neoplasias that present HE include rare acute eosinophilic leukemia types. The most common type of chronic leukemia is chronic eosinophilic leukemia (CEL), which is frequently associated with the FIP1L1-PDGFRA rearrangement in endomyocardial fibrosis/thrombosis and other myeloid neoplasias with rearrangements, such as the 8p11 syndrome [19, 20]. Clonal eosinophilia is frequently observed in advanced cases of systemic mastocytosis [19, 21, 22].
\nLymphoid neoplasms may present HE, and in most cases, a T cell lymphoma is diagnosed. Nevertheless, in such patients with 8p11 syndrome and other rare entities, both eosinophils and lymphocytes may be involved in the neoplastic clonal processes [19, 21].
\nParaneoplastic conditions associated with hypereosinophilia. Different types of cancers may be preceded or accompanied by eosinophilia. Cancers associated with HE include lung, gastrointestinal tract, pancreas, and thyroid adenocarcinomas, gynecologic tumors, and skin cancer. Although pathogenesis is unclear, there is a widely accepted hypothesis stating that carcinogenic cells or cancer or the cancer microenvironment around fibroblasts produce eosinophilopoietic cytokines [19, 23].
\nIdentification and quantification.
\nClassic methodology: Clinical manifestations and diagnosis depend on the type of disease and other factors, where different organs may be involved in patients with HES, for example, skin, gastrointestinal tract, heart, and central nervous system.
\nIn order to establish an HES diagnosis, it is recommended to include clinical and laboratory parameters, such as:
Physical exam of organs and body systems
Laboratory exams: white blood cell count (eosinophils, basophils, neutrophils), hemoglobin, platelet count, B12 vitamin, hepatic enzymes, kidney function tests, and urinalysis
Organic functional tests: electrocardiogram, echocardiogram, pulmonary function tests, chest computed tomography and radiography, abdominal ultrasound, and normal endoscopic study [19]
Molecular detection of some translocations, such as TCR, BCR/ABL1, JAK2 V617F, KITD816V, PDGFRA/PDGFRB, and FGR1
Immunoglobulins rearrangements are detected by real-time polymerase chain reaction with TaqMan molecular probes, such as TCR, BCR/ABL1, JAK2 V617F, KITD816V, PDGFRA/PDGFRB, and FGR1. The most recommended bone marrow exams are cytogenetic assays and fluorescence in situ hybridization (FISH)—other studies which do not include molecular detection are tissue immunohistochemistry and histology (Figure 4) [16].
\nFlow diagram to perform real-time PCR. In a simplified way, the preparation of the sample with its corresponding primer and the distribution of the samples for its reaction are shown, which can be seen in real time by monitoring the amplification as the cycles in the thermal cycler pass.
The WHO defines an ADR to any predictable noxious reaction that appears at therapeutic doses, depends on the doses, and is related to pharmacological actions. Other unpredictable reactions: hypersensitivity or allergic (DHRs) associated with immunological mechanisms, susceptibility (atopy), and polymorphism (pharmacogenetic, MHC-HLA) [24, 25, 26, 27].
\nIt is considered as a public health problem due to its high morbidity and mortality being 20%; hence, the importance of its clinical diagnosis and laboratory tests is being considered at all stages of life (prenatal, postnatal, childhood, adolescence, adult, and older adult).
\nMedications are usually non-immunogenic haptens of different types:
\nPro-haptens. Drugs are generally non-immunogenic haptens of different types: Pro-haptens (non-active reagents) low molecular weight chemicals of less than 1000 D; examples aromatic, heterocyclic, sulfonamides, OH, halogens, resonance, and beta-lactam are processed and presented in the CPA-MHC context and produce a humoral response, IgE, IgG and IgM or cellular.
\nActive reagents: aromatic, polar, with nitrogen, to induce an immune response CPA-MHC.
\nInert TCR pi (pharmacological interaction with immune receptors): Some drugs are able to bind non-covalently to TCR pi receptors pre-developed by a previous immune response to a non-covalently reversible drug and signaling toward a response of hypersensitivity and explain the rapid appearance of symptoms, some cross reactions to the drug, or its metabolites.
\nPi concept and HLA restriction in hypersensitivity: In the pi concept, drugs primarily activate TCR, for example, abacavir associated with the HLA-B * 5701 allele in whites, Stevens-Johnson syndrome (SJS) with carbamazepine treatment in Chinese associated in patients with the HLA-B * 1502, and HLA-B * 5801 allele in allopurinol-induced adverse reactions such as SJS and toxic epidermal necrolysis (TEN) [28, 29, 30, 31].
\nHypersensitivity is an exacerbated immune response, which produces a clinical picture with dermal, systemic disorders, and sometimes sudden death. In 1930 Coombs systematized these reactions according to the period of time in which the symptoms appear, and the dose of challenge has been fundamental to guide the diagnosis, treatment, and monitoring. It has many points in common with autoimmunity, where the antigens are their own; in the case of allergies to medications, the antigens are allergens: drugs or metabolic derivatives. Hypersensitivity reactions require that the individual has been previously sensitized or exposed to at least the antigens in question. The classification of allergic or hypersensitivity reactions into four types (I, II, III, and IV) and subsequently Pichler in 2003 proposed the subdivision of type IV into IVa, IVb, IVc, and IVd (Table 1) [28, 29].
\nType | \nType of immune response | \nClinical symptoms | \nIn vitro diagnostics | \nIn vivo diagnostics | \n
---|---|---|---|---|
I | \nMeasured by IgE eosinophils, mast cells, and basophils (immediate) | \nUrticaria Angioedema Rhinitis Bronchospasm Anaphylaxis | \nIgE specific Serum tryptase Cell stimulation test (CAST) BAT(MDB, CD63) | \nCutaneous tests (prick, intradermal) Challenge tests Proving tests [Coombs] | \n
II | \nCytotoxicity dependent on IgG and IGM antibodies (not immediate) and complement | \nHemolytic Anemia Thrombocytopenia Neutropenia Autoimmunity | \nCoombs test Ab vs. platelets Ab vs. neutrophils | \nOnly challenges to the drug can make diagnosis but are high risk [Coombs] | \n
III | \nDeposit of immunocomplexes [IgG and IgM] (not immediate) Complement or FcR | \nSerum disease Vasculitis, LES-like by medications Glomerulonephritis drug | \nC3, C4, ANA, ANCA, CCP, antithyroid, etc. Liver and kidney function tests Pathological anatomy | \nBiopsies with immunofluorescence [Coombs] | \n
IVa | \nTH1 (IFNγ), TNFα, IL12, and macrophages (late) | \nContact dermatitis | \nLymphocyte transformation test (LT or BT), MLIF, cytotoxic T lymphocyte precursors (CTLp), cytokines (ELISA, PCR) | \nPatch tests [Pichler] | \n
IVb | \nTH2 (IL-4, IL5, IL13) eosinophils | \nMaculopapular eruptions (MPE) with eosinophilia (DRESS) | \nCBC with check eosinophil cellularity, atypical lymphocytes MLIF, BT, LT | \nPatch tests [Pichler] | \n
IVc | \nCLT, CD4/CD8 (perforin, granzyme B, Fas L) | \nContact dermatitis, maculopapular, and bullous diseases(SJS), TEN | \nMLIF, liver function tests, CD4/CD8 (death keratinocytes) Activity of IgM vs. herpes virus, Epstein-Barr, and cytomegalovirus (CMV) | \nPatch tests [Pichler] | \n
IVd | \nT cells, IL8, CXCL8 cells Neutrophils Inflammation | \nAcute generalized exanthemic pustulosis (AGEP) pharmacodermias associated with neutrophilia | \nCBC T cells CD4/CD8 | \nPatch tests [Pichler] | \n
Hypersensitivity classification according to the Gell and Coombs modified by Sell, Pichler, and ICON.
Hypersensitivity reactions require that the individual has been previously sensitized or exposed at least once to the antigens in question. The classification of allergic or hypersensitivity reactions into four types (I, II, III, and IV) and subsequently Pichler in 2003 proposed the subdivision of type IV into IVa, IVb, IVc, and IVd [27, 28, 29].
Modified basophil degranulation (MBD): The test is a basophil activation test (BAT) which consists of incubating the basophils in vitro with the suspected drug to be carried out: epitope-paratope binding, activating the basophils and causing degranulation and release of the aforementioned content (specificity 100%, sensitivity 84.0%) [28, 29].
\nCD63 flow cytometry: Basophils with specific IgE when incubated with the suspected drug are activated by Fcε I receptors; high affinity and low affinity cause cross-linking and protein kinase signal transduction (MAP, PKC) that stimulate expression of the receptor (CD63) -gp53 (lysosomal-transmembrane protein tetraspanin LAMP-31) on the surface of the basophil while the eosinophilic expresses CD23 [30].
\nModified leukocyte migration inhibition factor (MLIF) type IV a, b, and c. Associated with anaphylactic degranulation: It has been reported that leukocytes including basophils (BAT-Chemotaxis) also play a role in directional chemotaxis; therefore, when microhematocrits are incubated in Bloom chambers with medications in two dilutions (1 and 0.1 mg/mL) in an RPMI medium, with negative and positive controls, at 37°C, the first (20 min at 2 hours) and delayed migration can be measured (4, 6, and 18 hours); the % of MLIF can also be calculated against the negative control, as well as the reference values (RV) for MLIF (0–25% inhibition of leukocyte migration) [29].
\nEosinophilia in the peripheral blood is a common cause in patients who consume medications, especially in developed countries, who are monitored and can restrict their consumption without changes. However, for the doctor, concern may arise in cases of impending hypersensitivity reaction (HSR). Severe HSRs associated with peripheral blood may include specific reactions of organs (heart, kidney, liver, lungs, joints, central nervous system, and skin) and adverse skin reactions (SCAR) where SJS, TEN, and DRESS are included [32, 33].
\nThe prolongation of eosinophilia can cause tissue damage, although without being clarified specifically, adding to the condition infections as another factor that preserves eosinophilia (parasitic and fungal infestations) or decreases (eosinopenia due to bacterial and viral infections). The diagnosis can be complicated because of the presence of the drug which worsens a preexisting eosinophilia, particularly in atopic patients [33].
\nDRESS is more common in adult patients than in children, with approximately 50 drugs being described, highlighting anticonvulsants (phenytoin, phenobarbital, and carbamazepine) and antibiotics as the main causes of the syndrome and, to a lesser extent, sulfate derivatives, antidepressants, NSAIDs, and antidiuretics [34]. There is no clear association between variability of the type of drug and the affected organ with the degree of eosinophilia, which can be mild or self-limited and severe when multisystemic complications are generated due to the presence of symptoms that are not appreciated in the mild form [32, 33].
\nOther proposals that lead to the pathogenesis of DRESS include detoxification defects at the time of the formation of reactive metabolites, slow acetylation, and reactivation of the human herpes virus (HHV-6-7) or EBV [34].
\nIn general, the diagnostic algorithm for eosinophilia linked to SCAR can be visualized as a hypersensitivity response type IVb (SJS and NET) and type IVc (DRESS), which in some way can highlight the pathogenesis proposals previously mentioned not only by DRESS but identify an atopic patient (Table 1).
\nEosinophils are leukocytes (white blood cells) found in the peripheral blood, hematopoietic, lymphatic organs, thymus, connective tissue, and digestive tract. They are identified and quantified by manual counting (Neubauer chamber), automated count with autoanalyzer hemocytometers (impedance, colorimetry, and differential in optical microscope), flow cytometry after the advent of monoclonal antibodies, currently the most used to identify surface markers and immunoenzymatic methods (ELISA, RAST, IMMUNOCAP) for cytoplasmic granules.
\nThe classification of eosinophilic diseases “eosinophilic disorders” was revised in 2008 and confirmed in 2016; its study focused on external (extrinsic) and internal (intrinsic) causes (optimized) and optimized and failed diagnosis by precise and timely diagnosis. The algorithms are used and started with the main pillar: The clinical history (clinical criteria, anamnesis, and exploitative maneuvers leading to clinical laboratory algorithms, with initial, basic, and special tests including imaging, tomography, and X-rays to finally improve the prognosis and modify the natural history. The intrinsic and extrinsic disorder algorithm planting is different; this is due to the recognition of molecular altered T cell clones, bone marrow studies, and markers of apoptotic genes, PCM1-JAK2, Fas L, and bcl2.
\nSome allergies to medications with symptomatology related to specific organ and severe cutaneous against antiepileptics (phenytoin, phenobarbital, carbamazepine) as well as other medications (antibiotics, NSAIDs, antidiuretics) can be related, which rethinks the proposed immunological response algorithm not only in basophil evaluation but also the search for eosinophils in flow cytometry or optical microscopy to assess not only damage but neutralization (eosinophil histaminase).
\nCorticosteroids are considered the first line of treatment because of their potent anti-eosinophilic effect for disease control, prognosis, and prevention. So the new treatment alternatives could displace steroids with monoclonal antibodies such as the IL-5 inhibitor that show less long-term toxicity.
\nThanks to the headquarters and staff of the Department of Allergy and Immunology of the Juarez Hospital of Mexico, Dr. Ruben Humberto Meyer Gomez of the Angeles Hospital, and the laboratory technician Isabel Guerrero Vargas of the LCEIL Laus Deo.
\nThere is no conflict of interest.
\n\n absolute eosinophil count hypersensitivity reaction severe cutaneous adverse reaction Stevens-Johnson’s syndrome toxic epidermal necrolysis drug rash eosinophilia and systemic symptoms complete blood count drug hypersensitivity reaction
“Scientific progress is fueled by collaboration. By democratizing the world’s scientific research, making it freely available to all, we want to inspire greater opportunity for collaboration, speed of discovery and scientific progress.”
\n\n--IntechOpen
",metaTitle:"Sponsors",metaDescription:"“Scientific progress is fueled by collaboration. By democratizing the world’s scientific research,\nmaking it freely available to all, we want to inspire greater opportunity for collaboration, speed of discovery and scientific progress.”\n\n--IntechOpen",metaKeywords:null,canonicalURL:"/page/sponsors-humans-in-space-program",contentRaw:'[{"type":"htmlEditorComponent","content":"Open Access is in the heart of the Humans in Space program as it removes barriers and allows everyone to freely access the research published. However, open access publishing fees also pose a barrier to many talented authors who just can’t afford to pay.
\\n\\nHumans in Space program aims to remove this barrier and pursue a model under which none of our authors will need to pay for publication and the editors will receive a budget for their editorial work.
\\n\\nWe are currently in the process of collecting sponsorship. If you have any ideas or would like to help sponsor the program, we’d love to hear from you. Contact: Natalia Reinic Babic at natalia@intechopen.com. All of our IntechOpen sponsors are in good company The research in past IntechOpen books and chapters have been funded / sponsored by:
\\n\\nOpen Access is in the heart of the Humans in Space program as it removes barriers and allows everyone to freely access the research published. However, open access publishing fees also pose a barrier to many talented authors who just can’t afford to pay.
\n\nHumans in Space program aims to remove this barrier and pursue a model under which none of our authors will need to pay for publication and the editors will receive a budget for their editorial work.
\n\nWe are currently in the process of collecting sponsorship. If you have any ideas or would like to help sponsor the program, we’d love to hear from you. Contact: Natalia Reinic Babic at natalia@intechopen.com. All of our IntechOpen sponsors are in good company The research in past IntechOpen books and chapters have been funded / sponsored by:
\n\n